THE BUSINESS expects to total advanced preclinical proof-of-concept research in Parkinson’s disease during the course of the year and programs to report additional data at a scientific conference in the second half of 2010. Additionally, Amicus announced today that its second business lead preclinical system using the pharmacological chaperone strategy is for the treating Alzheimer’s disease. THE BUSINESS expects to complete initial proof-of-concept studies during 2010 and record data in the second half of 2010. 2010 Financial Guidance Amicus expects to begin with 2010 with a money balance of approximately $78 million.Caris Life Sciences happens to be conducting and initiating additional studies of Caris Focus on Now molecular tumor profiling through collaboration with leading organizations and cancer centers, such as University of North Breastlink and Carolina. The breadth of the solutions is expected to help the hospital drive proactive and responsive individual care across all configurations. ‘Our objective is to make a single individual record,’ said Mike McDevitt, Kids's of Alabama's Executive Vice President/CIO of Technology and Facilities.